EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer

Chae A Kim iD, Jungmin Yoo iD, Won Gu Kim iD, Tae Yong Kim iD, Won Bae Kim iD, Min Ji Jeon iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Chae A Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Lung Neoplasms, Pleural Effusion, Malignant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant pleural effusion (MPE) from differentiated thyroid cancer (DTC) is rare and carries a poor prognosis. This study evaluated clinical outcomes and the impact of multikinase inhibitor (MKI) therapy in patients with MPE from DTC. In this retrospective cohort study of 184 DTC patients with lung metastases, 31 (17%) had MPE. After excluding 10 with non-malignant effusion, 174 were analyzed. Patients with MPE were older (P < 0.001) at DTC diagnosis, had higher T stage (P = 0.004), developed pleural metastases earlier (P = 0.016), and had more frequent macro- and polymetastatic lung lesions (P < 0.001) than those without MPE. All MPE cases were radioactive iodine-refractory and developed a median of 6.3 years after DTC diagnosis. Symptomatic MPE occurred in 22 patients (71%), all requiring drainage, while 9 (29%) had asymptomatic MPE. Symptomatic MPE was associated with worse overall survival (OS) compared to patients without MPE (adjusted hazard ratio (HR) 4.62, 95% confidence interval (CI) 2.49–8.57, P < 0.001). Notably, patients initiating MKI therapy for symptomatic MPE had the worst OS (adjusted HR 9.78, 95% CI: 3.52–27.13, P < 0.001). Median OS after MPE diagnosis was 13 months. Symptomatic MPE also had worse post-MPE survival compared to asymptomatic MPE (adjusted HR 5.73, 95% CI: 1.52–21.52, P = 0.009). MKI therapy did not significantly improve OS or progression-free survival after MPE onset. MPE in DTC patients with lung metastases indicates poor prognosis, especially when symptomatic. MKI therapy showed limited survival benefits after MPE onset. Early identification and proactive management of patients at high risk of MPE may improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsLung NeoplasmsPleural Effusion, MalignantHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisAged, 80 and overProtein Kinase Inhibitors

Stichwörter der Autor:innen

differentiated thyroid cancerlung metastasismalignant pleural effusionmultikinase inhibitorprognosis

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Endocrinology and Metabolism, Inha University College of Medicine, Incheon, Republic of Korea.
  • Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.

ORCID-Profile: Chae A Kim, Jungmin Yoo, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Min Ji Jeon

Zitieren

APA

Kim, C. A., Yoo, J., Kim, W. G., Kim, T. Y., Kim, W. B., & Jeon, M. J. (2025). Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0190

Vancouver

Kim CA, Yoo J, Kim WG, Kim TY, Kim WB, Jeon MJ. Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0190

BibTeX
@article{Kim2025,
  author = {Kim, Chae A and Yoo, Jungmin and Kim, Won Gu and Kim, Tae Yong and Kim, Won Bae and Jeon, Min Ji},
  title = {Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0190}
}
Kostenlos starten →